Clinical trial · Observational
Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)
NCT06626386CI-TRIAL-00081276PSA-CaprecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the PSA-Cap study is to test the comparability of measurements of total PSA in serum from venipuncture and in serum from capillary blood using anonymized diagnostic blood samples from patients. Furthermore, a stability test of the samples is carried out after storage at room temperature for 24, 72/96 and 168 hours. Particular attention is paid to the comparability of the measurement results and the influence of the transportation time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PSA testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Accuracy of PSA measurement in capillary blood vs. venous blood
- timeFrame
- After 0 h, 1 d, 3/4 d and 7 d
Secondary outcomes (1)
- measure
- PSA stability in serum fraction of both samples (capillary and venous)
- timeFrame
- After 0 h, 1 d, 3/4 d and 7 d
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Men aged from 45 to 70 years * Informed consent for PSA measurement for prostate cancer screening Exclusion Criteria: * Patients unable to give consent
References
Publications (0)
Data not yet available
No reference posted for this study.